The Life Sciences Discovery Fund (LSDF) announced today $3.7M in research and development grants. Stella Therapeutics was awarded $250,000 to complete preclinical testing of a novel small-molecule treatment for glioblastoma multiforme, a typically fatal brain cancer. The full release from the LSDF can be viewed here.
July 2013: Stella Therapeutics spotlighted as one of 17 University of Washington spin out companies.
- Cross Cut: What's Driving UW's new business boom?
- GeekWire: Welcome to startup U: University of Washington beats goal with 17 new startups in 12 months.
- The Seattle Times: Human cells on a chip and more: A virtual tour of UW startup showcase.
Stella Therapeutics obtains exclusive license to novel Glioblastoma Multiforme therapy from the University of Washington and University of Montana
Stella Therapeutics is awarded a Phase 1 SBIR from the National Cancer Institute of the National Institutes of Health to develop the Company's therapy for the aggressive brain cancer, Glioblastoma Multiforme.